Glaukos Corp (GKOS) — Quality & forensics
As of 2026-11-04 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 14
- Quality 29
- Growth 89
- Balance sheet 62
- Cash quality 49
- Capital allocation 12
- Momentum 97
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the GKOS chart & overview · the earnings record
FAQ · from the current data · as of 2026-11-04
Quick answers
What is Glaukos Corp's Closelooknet quality reading?
The composite reads 51/100 across 7 modules, as of 2026-11-04: valuation 14, quality 29, growth 89, balance sheet 62, cash quality 49, capital allocation 12, momentum 97. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Glaukos Corp's Altman Z-Score?
34.16, which sits in the safe zone (above 2.99) as of 2026-11-04. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Glaukos Corp's Piotroski F-Score?
3 of 8, as of 2026-11-04. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Glaukos Corp's Beneish M-Score indicate?
-2.62 — below the −1.78 manipulation-risk threshold, as of 2026-11-04. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Medical Devices. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- DXCM DexCom Incindustry
- CEVI.ST CellaVision ABindustry
- GMED Globus Medicalindustry
- SECT-B.ST Sectra AB (publ)industry
- SNN Smith & Nephew SNATS Incindustry
- SOON.SW Sonova H Agindustry
- PACB Pacific Biosciences of Californiaindustry
- MED.SW Medartis Holding AGindustry
- ENOV Enovis Corpindustry
- PHG Koninklijke Philips NV ADRindustry
- QSI QuantumSi Incindustry
- AXGN Axogen Incindustry
- LIVN LivaNova PLCindustry
- IRTC iRhythm Technologies Incindustry
- ZBH Zimmer Biomet Holdings Incindustry
- DEMANT.CO Demant A/Sindustry
- HAE Haemonetics Corporationindustry
- CNMD CONMED Corporationindustry
- MDT Medtronic PLCindustry
- UFPT UFP Technologies Incindustry